COMMUNIQUÉS West-GlobeNewswire

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
17/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75 [...]
New Life Expands Prestige Recovery Services To The Middle East
17/09/2025
MARBELLA, Spain, Sept. 17, 2025 (GLOBE NEWSWIRE) -- New Life announces expansion of its luxury wellness and recovery services to Dubai and Abu Dhabi through a strategic partnership with Aims Healthcare. New Life Expands [...]
Communiqué de presse : EADV : Les résultats de l’étude de phase 2a montrent que le brivekimig de Sanofi est efficace dans le traitement de l’hidrosadénite suppurée
17/09/2025
EADV : Les résultats de l’étude de phase 2a montrent que le brivekimig de Sanofi est efficace dans le traitement de l’hidrosadénite suppurée Dans l’étude de phase 2a, le brivekimig a entraîné des améliorations [...]
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
17/09/2025
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in [...]
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases
17/09/2025
Positive safety and tolerability profile of NAV-240 in Phase 1a study support further development Phase 1b study fully enrolled and data expected in early 2026 Further clinical development of NAV-240 to begin in early [...]
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
17/09/2025
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions [...]
Oruka Therapeutics Announces $180 Million Private Placement
17/09/2025
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the [...]
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
17/09/2025
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative treatment for patients on peritoneal dialysis (PD), today [...]
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
16/09/2025
WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration (“FDA”) 510(k) clearance [...]
Theratechnologies reçoit l’approbation définitive du tribunal relativement au plan d’arrangement proposé visant son acquisition par Future Pak
16/09/2025
MONTRÉAL, 16 sept. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade de la commercialisation, a annoncé aujourd’ [...]
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
16/09/2025
MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“ Theratechnologies ” or the “ Company ”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has [...]
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
17/09/2025
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapies Cancer Research UK’s Centre for Drug [...]
Cirtec Medical Welcomes Chris Cleary to its Board of Directors
16/09/2025
BROOKLYN PARK, Minn., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical is pleased to announce that Chris Cleary has been appointed to its Board of Directors. Chris brings over thirty years of experience in corporate [...]
PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation “BGXXQ” Q and A
16/09/2025
Fort Lauderdale, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PharmAGRI Capital Partners today announced its strategic focus on capturing a $10 billion total addressable market (TAM) in federal procurement of plant-based [...]
Sharecare, AWS, CLEAR, and Georgia Department of Community Health to discuss bringing CMS’s health tech ecosystem vision to life at Health Connect South
16/09/2025
During panel discussion, Sharecare Co-Founder and Executive Chairman Jeff Arnold to highlight company’s next-generation, AI-enabled health navigation experience, AskMD ATLANTA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- [...]
Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
16/09/2025
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment [...]
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
16/09/2025
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary clinical data and KO-2806 [...]
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
16/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 [...]
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
16/09/2025
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of [...]

Pages